Medexus Pharmaceuticals (TSE:MDP) Trading 1.6% Higher - Time to Buy?

Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) was up 1.6% during mid-day trading on Wednesday . The stock traded as high as C$2.51 and last traded at C$2.50. Approximately 33,700 shares traded hands during trading, a decline of 19% from the average daily volume of 41,850 shares. The stock had previously closed at C$2.46.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MDP shares. Stifel Canada raised shares of Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research report on Monday, August 12th. Stifel Nicolaus increased their price objective on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a "buy" rating in a research report on Thursday, August 22nd. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, June 26th. Finally, Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a research report on Monday, September 30th.

Medexus Pharmaceuticals Price Performance

The company has a market capitalization of C$63.53 million, a P/E ratio of 51.80 and a beta of 1.96. The company's 50-day moving average price is C$2.55 and its two-hundred day moving average price is C$2.11.

Medexus Pharmaceuticals (TSE:MDP - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported C$0.11 earnings per share for the quarter, topping the consensus estimate of C$0.04 by C$0.07. Medexus Pharmaceuticals had a net margin of 1.00% and a return on equity of 3.95%. The business had revenue of C$37.33 million during the quarter, compared to analysts' expectations of C$36.95 million. On average, analysts anticipate that Medexus Pharmaceuticals Inc. will post 0.1633166 earnings per share for the current fiscal year.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.